Biotechnology News and Research RSS Feed - Biotechnology News and Research

Cellular Research announces start of early access program for Precise assays

Cellular Research announces start of early access program for Precise assays

Cellular Research announced today the start of an early access program for its Precise assays and is currently making the product available to 10 sites. [More]
Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. [More]

Global life science reagents market to grow at 10.8% CAGR from 2013 to 2019

According to a new market report published by Transparency Market Research "Life Science Reagents Market(Products- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and Others; End Users- Commercial and Contract Manufacturers, Research and Academic Institutions, Clinical Laboratories, and Forensic Laboratories)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019", the global life science reagents market was valued at USD 12.44 billionin 2012 and is expected to grow at a CAGR of 10.8% from 2013 to 2019, to reach an estimated value of USD 25.73 billion in 2019. [More]
Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir Biosciences, Inc., a biotechnology company developing therapeutics to treat infectious diseases, has announced intentions to develop its lead drug candidate, GBV006, for the treatment of the current Ebola Virus outbreak in West Africa. Globavir will seek approval for the use of GBV006, a combination of Food and Drug Administration approved drugs, through an established compassionate use regulatory pathway. [More]
ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

Immune Targeting Systems, specializing in the development of novel T cell immune therapies, has been developing an exciting new T cell vaccine (FlunisynTM) designed to protect humans from all strains of seasonal and pandemic influenza A. [More]

HUYA Bioscience International announces strategic partnership with CZCBD

HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD). [More]

China Pharma Holdings' Q2 2014 revenue decreases by 24% to $6.1 million

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its financial results for the three months ended June 30, 2014. [More]
Dyadic's net product related revenue for Q2 2014 increases 28% to $4.9 million

Dyadic's net product related revenue for Q2 2014 increases 28% to $4.9 million

Dyadic International, Inc., a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced financial results for the second quarter ended June 30, 2014. [More]
University of California launches 14 commercial startups in a year

University of California launches 14 commercial startups in a year

The University of California, Davis, launched 14 commercial startups during the past year to June 30 - the largest number of new ventures based on UC Davis technology to be started in a single year. [More]
Babies suffering from life-threatening bacterial infections could benefit from improved treatment

Babies suffering from life-threatening bacterial infections could benefit from improved treatment

Babies suffering from life-threatening bacterial infections such as sepsis could benefit from improved treatment, thanks to a ground-breaking study. [More]
Health institutions tackle high rate of preterm birth

Health institutions tackle high rate of preterm birth

An estimated 15 million babies are born preterm every year and more than one million die within the first 30 days after birth. [More]
Novogen declares shareholder meeting results

Novogen declares shareholder meeting results

Australia-US biotechnology company, Novogen Ltd., an oncology and degenerative diseases drug development company, today announced the results of its General Meeting of Shareholders, which was held on August 12 in Sydney, Australia. [More]
Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS). [More]
Heart failure is major public health burden in many LMICs

Heart failure is major public health burden in many LMICs

Heart failure is a major public health burden in many low- and middle-income countries (LMICs), with substantial variation in the presentation, causes, management, and outcomes of heart failure across different LMICs, according to a study published in this week's PLOS Medicine. [More]
Sanofi, PATH announce delivery of first large-scale batches of antimalarial treatments

Sanofi, PATH announce delivery of first large-scale batches of antimalarial treatments

Sanofi and PATH today announced the delivery of the first large-scale batches of antimalarial treatments manufactured with a new semisynthetic artemisinin derivative to malaria-endemic countries in Africa. [More]
Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C. [More]
Scientists aim to understand and treat painful bladder condition

Scientists aim to understand and treat painful bladder condition

Taking advantage of technology that can analyze tissue samples and measure the activity of thousands of genes at once, scientists at Wake Forest Baptist Medical Center are on a mission to better understand and treat interstitial cystitis (IC), a painful and difficult-to-diagnose bladder condition. [More]
First peer-reviewed comprehensive expert guidance on the use of neurostimulation for pain

First peer-reviewed comprehensive expert guidance on the use of neurostimulation for pain

Reflecting groundbreaking international consensus regarding a group of rapidly evolving medical interventions for chronic pain, the International Neuromodulation Society announced it will soon publish the first peer-reviewed comprehensive expert guidance on the appropriate use of neurostimulation for pain. [More]
Researchers create synthetic molecule that can cause cancer cells to self-destruct

Researchers create synthetic molecule that can cause cancer cells to self-destruct

Researchers from The University of Texas at Austin and five other institutions have created a molecule that can cause cancer cells to self-destruct by ferrying sodium and chloride ions into the cancer cells. [More]
Oncothyreon reports decreased net operating loss in Q2 2014

Oncothyreon reports decreased net operating loss in Q2 2014

Oncothyreon Inc. today reported financial results for the second quarter ended June 30, 2014. Loss from operations decreased to $7.8 million for the three months ended June 30, 2014 compared with $18.0 million for the comparable period in 2013, and decreased to $15.0 million for the six months ended June 30, 2014 compared with $26.0 million for the comparable period in 2013. [More]